[go: up one dir, main page]

AU2001280767A1 - Peptide-mediated delivery of molecules into cells - Google Patents

Peptide-mediated delivery of molecules into cells

Info

Publication number
AU2001280767A1
AU2001280767A1 AU2001280767A AU8076701A AU2001280767A1 AU 2001280767 A1 AU2001280767 A1 AU 2001280767A1 AU 2001280767 A AU2001280767 A AU 2001280767A AU 8076701 A AU8076701 A AU 8076701A AU 2001280767 A1 AU2001280767 A1 AU 2001280767A1
Authority
AU
Australia
Prior art keywords
peptide
molecules
cells
mediated delivery
mediated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001280767A
Inventor
John Archdeacon
Gilles Divida
Joseph Fernandez
Frederic Heitz
Kyle Horndorp
Jean Mery
May Morris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Active Motif Inc
Original Assignee
Centre National de la Recherche Scientifique CNRS
Active Motif Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Active Motif Inc filed Critical Centre National de la Recherche Scientifique CNRS
Publication of AU2001280767A1 publication Critical patent/AU2001280767A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2001280767A 2000-07-31 2001-07-26 Peptide-mediated delivery of molecules into cells Abandoned AU2001280767A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22193200P 2000-07-31 2000-07-31
US60221932 2000-07-31
PCT/US2001/023406 WO2002010201A2 (en) 2000-07-31 2001-07-26 Peptide-mediated delivery of molecules into cells

Publications (1)

Publication Number Publication Date
AU2001280767A1 true AU2001280767A1 (en) 2002-02-13

Family

ID=22830020

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001280767A Abandoned AU2001280767A1 (en) 2000-07-31 2001-07-26 Peptide-mediated delivery of molecules into cells

Country Status (5)

Country Link
US (1) US6841535B2 (en)
EP (1) EP1305333A4 (en)
AU (1) AU2001280767A1 (en)
CA (1) CA2417454A1 (en)
WO (1) WO2002010201A2 (en)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807746A (en) * 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
US6495518B1 (en) * 1994-06-13 2002-12-17 Vanderbilt University Method for importing biologically active molecules into cells
US7790171B1 (en) * 2000-08-25 2010-09-07 Centre National De La Recherche Scientifique (C.N.R.S.) Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase
US6850788B2 (en) 2002-03-25 2005-02-01 Masimo Corporation Physiological measurement communications adapter
CN1650005B (en) * 2002-04-25 2010-12-08 东亚合成株式会社 Antibacterial polypeptide and its application
WO2003094973A1 (en) * 2002-05-08 2003-11-20 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Agent and method for transporting biologically active molecules in cells
US7105347B2 (en) * 2002-07-30 2006-09-12 Corning Incorporated Method and device for protein delivery into cells
JP3996028B2 (en) * 2002-09-30 2007-10-24 株式会社日本触媒 Method for intracellular introduction of protein or peptide
CA2506714A1 (en) * 2002-11-26 2004-06-10 University Of Massachusetts Delivery of sirnas
FR2849603B1 (en) * 2003-01-07 2006-09-08 Centre Nat Rech Scient COMPOSITION FOR THE INTRACELLULAR TRANSPORT OF MACROMOLECULES OR BIOLOGICAL PARTICLES
WO2004078213A1 (en) * 2003-03-06 2004-09-16 Chikako Nishigori Composition for target substance introduction and method of target substance introduction
WO2005049819A1 (en) 2003-10-29 2005-06-02 Toagosei Co., Ltd. Antibacterial peptide and utilization of the same
WO2005047531A1 (en) * 2003-11-14 2005-05-26 Garvan Institute Of Medical Research Assay for pkc-beta activation of phosphorylation of myosin heavy chain polypeptide
US7691607B2 (en) * 2004-02-09 2010-04-06 The Regents Of The University Of California Expression system of NELL peptide
US7446099B2 (en) 2004-02-27 2008-11-04 Nitto Denko Corporation Compositions and methods for biodegradable polymer-peptide mediated transfection
JP4635046B2 (en) * 2004-04-20 2011-02-16 マリナ・バイオテック・インコーポレーテッド Methods and compositions for enhancing delivery of double stranded RNA or double stranded hybrid nucleic acids for modulating gene expression in mammalian cells
US7514530B2 (en) * 2004-04-26 2009-04-07 Centre National De La Recherche Scientifique Peptide carrier for delivering siRNA into mammalian cells
US20060040882A1 (en) * 2004-05-04 2006-02-23 Lishan Chen Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
JP4507080B2 (en) 2004-07-30 2010-07-21 東亞合成株式会社 Antibacterial peptides and their use
JP4730584B2 (en) 2004-12-06 2011-07-20 東亞合成株式会社 Antibacterial peptides and their use
EP1864134A4 (en) * 2005-02-07 2010-10-20 Univ Columbia METHODS OF TREATING OR PREVENTING HORMONE-RESISTANT PROSTATE CANCER USING SMALL INTERFERING RNA SPECIFIC TO PROTOCADHERINE-PC, OR OTHER INHIBITORS OF PROTOCADHERINE-PC EXPRESSION OR ACTIVITY
ATE483158T1 (en) 2005-04-05 2010-10-15 Allergan Inc CLOSTRIDIAL TOXIN ACTIVITY TESTS
US7947279B2 (en) 2005-06-30 2011-05-24 The Trustees Of Columbia University In The City Of New York Peptide having hydrolase activity
JP5221368B2 (en) 2005-11-14 2013-06-26 サントル ナシオナル ドゥ ラ ルシェルシェサイアンティフィク（セエヌエールエス） Inhibitors of PARP activity and uses thereof
WO2007069090A2 (en) * 2005-12-06 2007-06-21 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2007066809A1 (en) 2005-12-06 2007-06-14 Tokyo Metropolitan Organization For Medical Research Protein which can serve as nucleus for polymerization of protein polymer, cell having the polymer introduced therein, and process for production of the cell
ATE490266T1 (en) * 2005-12-06 2010-12-15 Centre Nat Rech Scient PEPTIDES THAT PERMEATE INTO CELLS AS CARRIERS FOR MOLECULES
US8129187B2 (en) * 2005-12-13 2012-03-06 Kyoto University Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
US8278104B2 (en) * 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
AU2006325975B2 (en) * 2005-12-13 2011-12-08 Kyoto University Nuclear reprogramming factor
US20090227032A1 (en) 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
US8273867B2 (en) * 2006-02-10 2012-09-25 The Regents Of The University Of California Transducible delivery of siRNA by dsRNA binding domain fusions to PTD/CPPS
US20070281900A1 (en) * 2006-05-05 2007-12-06 Nastech Pharmaceutical Company Inc. COMPOSITIONS AND METHODS FOR LIPID AND POLYPEPTIDE BASED siRNA INTRACELLULAR DELIVERY
US20070269892A1 (en) * 2006-05-18 2007-11-22 Nastech Pharmaceutical Company Inc. FORMULATIONS FOR INTRACELLULAR DELIVERY dsRNA
CN101506368B (en) * 2006-07-12 2017-02-08 加利福尼亚大学董事会 Transduction of nucleic acids via reversible phosphotriester charge-neutralizing protecting groups
US9161696B2 (en) * 2006-09-22 2015-10-20 Masimo Corporation Modular patient monitor
US8840549B2 (en) * 2006-09-22 2014-09-23 Masimo Corporation Modular patient monitor
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
KR101138930B1 (en) * 2007-02-16 2012-04-25 (주) 에빅스젠 Composition for preventing and treating ???? comprising ??? ?? protein
JP2008307007A (en) * 2007-06-15 2008-12-25 Bayer Schering Pharma Ag Human pluripotent stem cell induced from human tissue-originated undifferentiated stem cell after birth
US9213999B2 (en) * 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
US20090047703A1 (en) * 2007-08-17 2009-02-19 University Of Maryland, Baltimore ERG-1 Peptides and Polynucleotides and Their Use in the Treatment and Diagnosis of Disease
GB0724253D0 (en) * 2007-12-12 2008-01-30 Fermentas Uab Transfection reagent
UA102247C2 (en) 2008-03-14 2013-06-25 Аллерган, Инк. IMMUNOLOGICAL ANALYSIS OF THE ACTIVITY OF BOTULIN TOXIN SEROTYPE A
CA2695522C (en) * 2008-05-02 2019-01-15 Kyoto University Method of nuclear reprogramming
AU2009246134B2 (en) 2008-05-16 2016-03-03 The Children's Hospital Of Philadelphia Genetic alterations on chromosomes 21q, 6q and 15q and methods of use thereof for the diagnosis and treatment of type I diabetes
EP2344519B1 (en) 2008-11-07 2016-09-28 The General Hospital Corporation C-terminal fragments of glucagon-like peptide-1 (glp-1)
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
KR101898557B1 (en) 2009-03-13 2018-09-14 알러간, 인코포레이티드 Cells Useful for Immuno-Based Botulinum Toxin Serotype A Activity Assays
US8455203B2 (en) 2009-03-13 2013-06-04 Allergan, Inc. Immuno-based retargeted endopeptidase activity assays
WO2010108824A1 (en) 2009-03-23 2010-09-30 Vib Vzw L-plastin antibodies and their use
WO2010137012A1 (en) 2009-05-25 2010-12-02 Ramot At Tel-Aviv University Ltd. Peptide therapy for amphiregulin mediated diseases
US8609617B2 (en) 2009-09-04 2013-12-17 University Of Miami KLF family members regulate intrinsic axon regeneration ability
US8741591B2 (en) 2009-10-09 2014-06-03 The Research Foundation For The State University Of New York pH-insensitive glucose indicator protein
US9856456B2 (en) 2009-10-12 2018-01-02 Thermo Fisher Scientific Baltics Uab Delivery agent
GB0917792D0 (en) * 2009-10-12 2009-11-25 Fermentas Uab Delivery agent
DK3252068T3 (en) 2009-10-12 2025-08-25 Larry J Smith METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION USING OLIGONUCLEOTIDE-BASED DRUGS ADMINISTERED IN VIVO OR IN VITRO
WO2011050039A2 (en) * 2009-10-22 2011-04-28 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Modular functional peptides for the intracellular delivery of nanoparticles
US9153112B1 (en) 2009-12-21 2015-10-06 Masimo Corporation Modular patient monitor
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
WO2011135222A2 (en) 2010-04-26 2011-11-03 Universite Joseph Fourier Use of peptides as transporters intended for the internalization of molecules of interest into target cells
CA2812940A1 (en) 2010-09-27 2012-04-12 The Children's Hospital Of Philadelphia Compositions and methods useful for the treatment and diagnosis of inflammatory bowel disease
EP2468303A1 (en) 2010-12-14 2012-06-27 Centre National de la Recherche Scientifique Functionalized nucleic acids and particles comprising them for the treatment of HIV infections
TWI404801B (en) * 2011-06-15 2013-08-11 The method and application of peptide-mediated mitochondrial delivery system
EP2729157B1 (en) 2011-07-06 2019-01-16 The General Hospital Corporation A pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1) for use in treatment
US9943269B2 (en) 2011-10-13 2018-04-17 Masimo Corporation System for displaying medical monitoring data
JP6104920B2 (en) 2011-10-13 2017-03-29 マシモ・コーポレイション Medical surveillance hub
US10149616B2 (en) 2012-02-09 2018-12-11 Masimo Corporation Wireless patient monitoring device
US10307111B2 (en) 2012-02-09 2019-06-04 Masimo Corporation Patient position detection system
JP6268164B2 (en) 2012-04-09 2018-01-24 ケース ウエスタン リザーブ ユニバーシティ Compositions and methods for inhibiting the activity of LAR family phosphatases
US10729777B2 (en) 2012-04-09 2020-08-04 Case Western Reserve University Compositions and methods for inhibiting the activity of LAR family phosphatases
WO2014005219A1 (en) * 2012-07-02 2014-01-09 Iprogen Biotech Inc. Intracellular protein delivery
CA2880869A1 (en) 2012-08-20 2014-02-27 The Regents Of The University Of California Polynucleotides having bioreversible groups
US9749232B2 (en) 2012-09-20 2017-08-29 Masimo Corporation Intelligent medical network edge router
US9382531B2 (en) 2012-10-22 2016-07-05 Wisconsin Alumni Research Foundation Induction of hemogenic endothelium from pluripotent stem cells
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
US10832818B2 (en) 2013-10-11 2020-11-10 Masimo Corporation Alarm notification system
US20160324944A1 (en) 2013-12-29 2016-11-10 Franco Venanzi Methods and compositions relating to p62/SQSTM1 for the treatment and prevention of inflammation-associated diseases
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
CA2923064C (en) 2014-02-20 2016-10-25 Cura Health Inc. Transdermal composition for treating pain
US10029012B2 (en) 2014-09-05 2018-07-24 University Of Pittsuburgh—Of The Commonwealth System Of Higher Education Peptide-mediated intravesical delivery of therapeutic and diagnostic agents
US10201610B2 (en) * 2014-10-20 2019-02-12 The University Of Western Australia Interference peptides and use thereof
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3337465B1 (en) 2015-08-21 2021-11-24 The Children's Hospital of Philadelphia Compositions and methods for use in combination for the treatment and diagnosis of autoimmune diseases
EP3344123B1 (en) 2015-08-31 2022-10-26 Masimo Corporation Wireless patient monitoring methods
AU2017248353A1 (en) 2016-04-07 2018-10-25 Case Western Reserve University TDP-43 mitochondrial localization inhibitor for the treatment of neurodegenerative disease
US10617302B2 (en) 2016-07-07 2020-04-14 Masimo Corporation Wearable pulse oximeter and respiration monitor
WO2018035380A1 (en) 2016-08-17 2018-02-22 Solstice Biologics, Ltd. Polynucleotide constructs
US11076777B2 (en) 2016-10-13 2021-08-03 Masimo Corporation Systems and methods for monitoring orientation to reduce pressure ulcer formation
KR101797167B1 (en) * 2016-11-09 2017-11-13 주식회사 바이오셀트란 Novel protein transduction domain and the usage thereof
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3645546A4 (en) 2017-06-30 2021-12-01 Solstice Biologics, Ltd. CHIRAL PHOSPHORAMIDITE AIDS AND METHOD FOR THEIR USE
CN111093684A (en) 2017-07-11 2020-05-01 凯斯西储大学 Compositions and methods for treating myelin disorders
EP3782165A1 (en) 2018-04-19 2021-02-24 Masimo Corporation Mobile patient alarm display
AU2019334965B2 (en) 2018-09-05 2025-01-23 Case Western Reserve University Methods and compositions for inducing neural plasticity
US12495968B2 (en) 2018-10-12 2025-12-16 Masimo Corporation System for transmission of sensor data using dual communication protocol
CN113170298B (en) 2018-10-12 2024-12-27 迈心诺公司 A system that transmits sensor data using a dual communication scheme
KR102246906B1 (en) * 2019-04-29 2021-04-30 주식회사 바이오셀트란 Cosmetic composition for anti-wrinkle with high skin or cell penetration capacity
US12410401B2 (en) 2019-06-06 2025-09-09 Wisconsin Alumni Research Foundation (Warf) Generation of functional neutrophils and macrophages from induced pluripotent stem cells in chemically defined conditions using transient expression of ETV2
WO2020252298A1 (en) * 2019-06-14 2020-12-17 The University Of North Carolina At Chapel Hill Compositions and methods for targeting the nucleosome remodeling and deacetylase complex
US12285437B2 (en) 2019-10-30 2025-04-29 The Research Foundation For The State University Of New York Reversing the undesirable pH-profile of doxorubicin via activation of a disubstituted maleamic acid prodrug at tumor acidity
WO2021189007A1 (en) 2020-03-20 2021-09-23 Masimo Corporation Remote patient management and monitoring systems and methods
USD980091S1 (en) 2020-07-27 2023-03-07 Masimo Corporation Wearable temperature measurement device
USD974193S1 (en) 2020-07-27 2023-01-03 Masimo Corporation Wearable temperature measurement device
WO2022025319A1 (en) * 2020-07-30 2022-02-03 주식회사 바이오셀트란 Soluble microneedle patch containing skin-permeable recombinant neuropeptide complex
EP3957721A1 (en) 2020-08-20 2022-02-23 Life & Brain GmbH Rapid production of human neuronal cultures with single cell resolution
USD1072837S1 (en) 2020-10-27 2025-04-29 Masimo Corporation Display screen or portion thereof with graphical user interface
CN113214822B (en) * 2021-04-12 2022-07-26 华南理工大学 AIE nanofiber probe for targeted staining of cell membrane and preparation method thereof
US20250002849A1 (en) 2021-09-01 2025-01-02 Dnovo Inc. Transdifferentiation of non-hair follicle stem cells to non-auditory induced hair follicle stem cells
WO2023049712A1 (en) 2021-09-22 2023-03-30 Masimo Corporation Wearable device for noninvasive body temperature measurement
USD1000975S1 (en) 2021-09-22 2023-10-10 Masimo Corporation Wearable temperature measurement device
WO2023070026A1 (en) 2021-10-20 2023-04-27 Dnovo Inc. Transdifferentiation of non-dermal papilla cells to dermal papilla cells
CN113845574A (en) * 2021-11-30 2021-12-28 百益美恒(北京)科技有限公司 Penetrating peptide TDP, fusion penetrating peptide protein, preparation method and application thereof
EP4432919A1 (en) 2022-01-05 2024-09-25 Masimo Corporation Wrist and finger worn pulse oximetry system
USD1048908S1 (en) 2022-10-04 2024-10-29 Masimo Corporation Wearable sensor
CN116003511A (en) * 2023-01-30 2023-04-25 安徽科技学院 Morchella-derived hypoglycemic peptide and application thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270163A (en) * 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5747253A (en) * 1991-08-23 1998-05-05 Isis Pharmaceuticals, Inc. Combinatorial oligomer immunoabsorbant screening assay for transcription factors and other biomolecule binding
FR2739621B1 (en) * 1995-10-05 1997-12-05 Centre Nat Rech Scient PEPTIDES FOR USE AS VECTORS FOR INTRACELLULAR ADDRESSING OF ACTIVE MOLECULES
WO2000018778A1 (en) 1998-09-29 2000-04-06 Phylos, Inc. Synthesis of codon randomized nucleic acids
US7790171B1 (en) * 2000-08-25 2010-09-07 Centre National De La Recherche Scientifique (C.N.R.S.) Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase
WO2002064057A2 (en) * 2001-02-15 2002-08-22 Baylor College Of Medicine Use of cell penetrating peptides to generate antitumor immunity

Also Published As

Publication number Publication date
WO2002010201A2 (en) 2002-02-07
US20030119725A1 (en) 2003-06-26
US6841535B2 (en) 2005-01-11
CA2417454A1 (en) 2002-02-07
EP1305333A2 (en) 2003-05-02
EP1305333A4 (en) 2006-04-12

Similar Documents

Publication Publication Date Title
AU2001280767A1 (en) Peptide-mediated delivery of molecules into cells
AU2001234567A1 (en) Guaranteed exactly once delivery of messages
AU5090200A (en) Culture chamber
AU2001291859A1 (en) Use of copolycarbonates
AU1803601A (en) Methods and compositions for the introduction of molecules into cells
AU6887401A (en) Delivery of remotely-ordered products
AU2001232020A1 (en) Floating drug delivery composition
AU2001238346A1 (en) Modification of biopolymers for improved drug delivery
AU2001248833A1 (en) Stable liquid preparation
AU2001267428A1 (en) Direct detection of individual molecules
AU2001260270A1 (en) Liposomes containing active substances
AU2001253521A1 (en) Haplotypes of the cxcr4 gene
AU2001274954A1 (en) Compositions and methods for delivery of a molecule into a cell
GB0022101D0 (en) Delivery of substances to cells
AU2001253386A1 (en) Haplotypes of the impdh2 gene
AU2001273541A1 (en) Haplotypes of the edg6 gene
AU2001258330A1 (en) New uses of imidazolylmethyl-pyridines
AU2001240017A1 (en) Human enzyme molecules
AU2001255330A1 (en) Haplotypes of the akr1b1 gene
AU5647101A (en) Over expression of the whn protein
AU2001292815A1 (en) Haplotypes of the scya8 gene
AU2001290603A1 (en) Haplotypes of the or11a1 gene
AU2001270608A1 (en) Peptide-mediated ocular cell transfection
AU2001288868A1 (en) Haplotypes of the gpr68 gene
AU2001266759A1 (en) Haplotypes of the acp2 gene